Evidence map›Paper›PMID 40827127›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)

The plasma p-tau217/BD-tau ratio improves biomarker short-term variability in memory clinic patients.

Frederikke Kragh Clemmensen, Fernando Gonzalez-Ortiz, Mathias Holsey Gramkow, Cristano Santos, Henrik Zetterberg, Kaj Blennow, Steen Gregers Hasselbalch, Kristian Steen Frederiksen, Anja Hviid Simonsen

Abstract read
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Brain-derived plasma p-tau217 shows enhanced dynamic range for Alzheimer's disease neuropathological change.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Frederikke Kragh ClemmensenDanish Dementia Research Centre, Department of Neurology Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark.
Fernando Gonzalez-OrtizDepartment of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden.
Mathias Holsey GramkowDanish Dementia Research Centre, Department of Neurology Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark.
Cristano SantosDepartment of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden.
Steen Gregers HasselbalchDanish Dementia Research Centre, Department of Neurology Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark.
Kristian Steen FrederiksenDanish Dementia Research Centre, Department of Neurology Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark.
Anja Hviid SimonsenDanish Dementia Research Centre, Department of Neurology Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAssessment of short-term intra- and inter-individual variability for Alzheimer's disease (AD) plasma biomarkers is essential for clinically relevant interpretation of biomarker levels. We hypothesized that the variability of plasma tau phosphorylated at threonine 217 (p-tau217) could be reduced by combining it with a tau marker, plasma brain-derived tau (BD-tau), as the p-tau217/BD-tau ratio.

methodsThree consecutive blood samples were collected from memory clinic patients within 36 days. Patients were dichotomized by cerebrospinal fluid (CSF) amyloidosis (Aβ+ = 29, Aβ- = 18). We compared intra- and inter-individual variability (coefficient of variation [CV]) in the plasma p-tau217/BD-tau ratio with p-tau217 alone and tested if kidney function, glycated hemoglobin, and body mass index (BMI) affected the variability. Finally, we compared the p-tau217/BD-tau ratio with CSF p-tau217.

resultsWe found that for Aβ+ individuals, the intra-individual variability of the plasma p-tau217/BD-tau ratio (CV 7.1% [95% confidence interval {CI} 5.6;8.4]) was lower than for p-tau217 alone (CV 9.4% [95% CI 7.4;11.5]). At the group level, the variability in the p-tau217/BD-tau ratio was reduced in both Aβ+ (CV 15.1% [95% CI 11.7;18.7]) and Aβ- (CV 18.4% [95% CI 13.0;23.8]) individuals compared to p-tau217 alone (Aβ+ CV 19.1 [15.0;23.4], Aβ- 27.1 [18.4;36.0]). Adjusting for estimated glomerular filtration rate, hemoglobin A1C, and BMI further reduced the inter-individual variability of p-tau217/BD-tau in the Aβ+ group. CSF p-tau217 showed higher correlation with plasma p-tau217/BD-tau (rho = 0.53, DISCUSSION: Our findings suggest that using the ratio of plasma p-tau217 to plasma BD-tau and accounting for the influence of peripheral confounders improves biomarker stability, which is important for the interpretation of longitudinal biomarker changes and to prevent misclassification. HIGHLIGHTS: The plasma p-tau217/BD-tau ratio lowered short-term intra- and, especially, inter-individual variability compared to the variability in plasma p-tau217 alone.Plasma BD-tau did not correlate with eGFR, HbA1c, or BMI, while plasma p-tau217 was significantly negatively associated with BMI.Adjusting for eGFR, HbA1c, and BMI further reduced the inter-individual variability of p-tau217/BD-tau.Additionally, CSF p-tau217 correlated better with plasma p-tau217/BD-tau than with p-tau217 alone.

Indexed as

Alzheimer's diseasebetween‐subject variabilitybrain‐derived tauplasma biomarkerp‐tau217p‐tau217/BD‐tau ratioshort‐term variabilitywithin‐subject variability

Identifiers

PMID40827127
PMCPMC12358005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.